MedTrace Logo

New Proteins in Body Fluids as Potential Biomarker for Alzheimer's Disease: a Pilot Study

NCT01773915 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 20

Last updated 2014-01-14

No results posted yet for this study

Summary

Alzheimer's disease (AD) is the most common neurodegenerative disorder afflicting the elderly. Currently, some biochemical tests performed on Cerebrospinal Fluid (CSF) samples have demonstrated to discriminate to some extend between AD and non-AD individuals based on the levels of tau, phospho-tau or Aβ42. We aim to investigate newly identified proteins whose levels increase during the Braak Stages of AD that are accessible in other body fluids such as blood, urine or saliva. The detection of these proteins would allow performing simple tests in case its levels were confirmed to be associated with the AD pathology.

Conditions

  • Alzheimer Disease, Late Onset

Sponsors & Collaborators

  • Universitaire Ziekenhuizen KU Leuven

    lead OTHER

Principal Investigators

  • Bart De Strooper · KU Leuven

  • Francesc Guix · KU Leuven

Eligibility

Min Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2012-12-31
Primary Completion
2014-01-31
Completion
2014-06-30

Countries

  • Belgium

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01773915 on ClinicalTrials.gov